Krystal Biotech, Inc. (KRYS): Shareholders' Equity
$1.22B
As of 2025-12-31
$1.36B
As of 2026-06-30
+32.7%
3-year compound annual growth
+33.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.22B | +28.9% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $946.38M | +21.5% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $778.64M | +49.1% | 2026-02-17, Balance as of period end |
| 2022-12-31 | $522.23M | -12.0% | 2025-02-19, Balance as of period end |
| 2021-12-31 | $593.58M | +103.2% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $292.08M | +43.9% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $202.91M | +79.2% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $113.23M | +128.9% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $49.47M | n/m | 2018-03-12, Balance as of period end |
| 2016-12-31 | $289.0K | n/a | 2018-03-12, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗